Here are five highlights:
1. Used to treat cervical total disc replacement, Mobi-C is intended to keep range of motion and flexibility intact after surgery.
2. The three studies illustrate Mobi-C’s short- and long-term safety, efficacy and patient satisfaction.
3. One study, “Prevalence, Progression, and Clinical Implications of Heterotopic Ossification after Cervical Disc Arthroplasty at 7 years,” found no patients underwent subsequent CTDR due to heterotopic ossification after treatment with the Mobi-C.
4. Another study, “Clinical Results of Cervical Total Disc Replacement with a Self-Adjusting Mobile Core Prosthesis after 10-Year Follow-Up,” revealed TDR with a device like Mobi-C was effective and safe.
5. The third study, “Reemergence of Symptoms after Successful Treatment with Cervical Disc Arthroplasty or Anterior Cervical Discectomy and Fusion between 2 to 5 years follow-up,” found cervical TDA with Mobi-C treatment was more effective than anterior cervical discectomy and fusion.
More articles on devices:
Vertera Spine raises $3M from 29 investors: 4 key notes
Aurora Spine, DJO Global, Zimmer Biomet & more: 9 device company key notes
Global bone screw system market to see growth through 2027: 6 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
